在美国定价46.5万美元的重磅药中国获批后至今未卖,传奇生物回应撤掉中国销售团队传闻

第一财经
Jun 16, 2025

近日关于传奇生物(LEGN.NS)已经取消了中国的销售和市场团队的消息在市场中传得沸沸扬扬。传奇生物旗下已实现商业化上市的产品,主要是CAR-T药物西达基奥仑赛注射液,这款药物最早在2022年2月获批美国上市,用于治疗成人患者复发或难治性多发性骨髓瘤,是中国首款走出国门的原创CAR-T细胞治疗药物。直到2024年8月份,这款药物才获批中国上市,用于治疗复发或难治性多发性骨髓瘤成人患者,既往接受过...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10